The atopic dermatitis (AD) market is on track to reach $16.7 billion across mature markets by 2030, according to data and analytics company GlobalData. 19 September 2024
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Danish dermatology specialist LEO Pharma has presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE). 5 September 2024
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
South Korea’s Celltrion yesterday announced the European Commission (EC) approval for the use of SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. 27 August 2024
Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. 23 August 2024
San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) yesterday announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program. 14 August 2024
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
BioNTech released positive top-line data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. 30 July 2024
California’s Arcutis Biotherapeutics, a biopharma developing innovations in immuno-dermatology, has announced the US commercial launch of Zoryve (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age six years. 30 July 2024
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
“Circle of Goodness,” one of Russia’s largest public funds, specializing on procurements of drugs for children with rare diseases, will begin procurements of the US drug Vyjuvek (beremagen heperpavec), which is designed for patients with epidermolysis bullosa (butterfly syndrome), reports The Pharma Letter’s local correspondent. 25 July 2024
US drugmaker AbbVie is eyeing a second approval for its JAK inhibitor Rinvoq (upadacitinib), just 11 weeks after announcing its first one. 31 October 2019
French pharma major Sanofi saw its share price dip a fraction by mid-morning, after posting lower third-quarter 2019 sales, hit by a fall in revenue at its primary care business and a drop in its vaccines business. 31 October 2019
Germany’s MorphoSys and Belgium’s Galapagos today announced the end of the clinical development program of MOR106 in atopic dermatitis. 30 October 2019
A Type II variation application has been submitted to the European Medicines Agency (EMA) seeking approval for Tremfya (guselkumab) to treat adults with active psoriatic arthritis (PsA). 23 October 2019
US pharma major Eli Lilly (NYSE: LLY) recently published results from its head-to-head clinical study showing that its interleukin (IL)-17A inhibitor Taltz (ixekizumab) has superiority versus Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Tremfya (guselkumab) in moderate-to-severe plaque psoriasis patients. 23 October 2019
The US Food and Drug Administration has approved Israel-headquartered skincare specialist Foamix Pharmaceuticals’ novel Amzeeq (minocycline) topical foam, 4%. 21 October 2019
Johnson & Johnson’s pharma arm, Janssen, has announced new long-term data from the open-label period of the Phase III VOYAGE 1 clinical trial of Tremfya (guselkumab). 18 October 2019
Shares in Belgian drugmaker UCB were buoyed by positive Phase III data for the firm’s key pipeline candidate, bimekizumab, on Thursday. 17 October 2019
Spanish dermatology specialist Almirall looked set to close 4% up on Friday following the publication of new data on its new psoriasis drug Ilumetri (tildrakizumab), aiding its efforts to commercialize the drug in Europe. 11 October 2019
The Switzerland-based company will be led in its next phase of growth and innovation by an experienced management team and board, with proven track records in building sustainable high-growth businesses in pharmaceutical and consumer industries. 9 October 2019
The US Food and Drug Administration has approved Aklief (trifarotene) Cream, 0.005% for the topical treatment of acne, making it the first new retinoid molecule to receive US FDA approval for the treatment of acne in more than 20 years. 7 October 2019
Following positive topline results announced in August, Eli Lilly has presented full data from the Phase IV IXORA-R study, at the Maui Derm NP+PA meeting. 3 October 2019
Sweden’s Moberg Pharma has entered into a license agreement granting Japan’s Taisho Pharmaceutical exclusive Japanese rights to MOB-015, a new topical treatment of onychomycosis based on Moberg's patented proprietary formulation of terbinafine. 1 October 2019
Positive top-line results from a second Phase III pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD), were released on Friday by US pharma giant Pfizer. 30 September 2019
Japanese drugmaker JCR Pharmaceuticals has withdrawn its application with the Ministry of Health, Labor and Welfare of Japan (MHLW) for additional marketing approval of Temcell HS Inj, allogeneic bone marrow-derived mesenchymal stem cells, for the indication of epidermolysis bullosa (EB) (development code: JR-031EB). 20 September 2019
A new report from industry analyst GlobalData finds that the market for hidradenitis suppurativa (HS) therapies is expected to grow from $898 million in 2018 to $1.81 billion in 2028, across the major markets. 19 September 2019
The National Institute for Health and Clinical Excellence (NICE), the health technology appraisal body in England and Wales, has issued its Final Appraisal Determination (FAD) recommending Takhzyro (lanadelumab) subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema (HAE). 18 September 2019
Spanish dermatology specialist Almirall has announced that Mike McClellan will join the company as new chief financial officer (CFO) on November 11, 2019. 18 September 2019
Epidermolysis bullosa (EB) is a class of rare diseases that result in fragile skin prone to injury and blistering.1 The last week in October is EB Awareness Week – an apt time to build knowledge on this severe condition for which common subtypes are estimated to occur in 1 in every 50,000 births globally across all ethnicities and genders.1 17 September 2019